Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Zealand boosts surgery and radiotherapy access drive

This article was originally published in Clinica

Executive Summary

The New Zealand government is seeking to almost treble the current growth in elective surgery activity, and to guarantee much faster access to radiotherapy. The measures are among six health targets that came into effect on July 1, replacing the previous set of 10 targets.

You may also be interested in...



After EUA, US Will Ship Only Half Of Doses For Pfizer, Moderna COVID-19 Vaccines

Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.

Medicare Walks Back Proposed Payment Policy For 505(b)(2) Physician Administered Drugs

CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to consider the issue.

Finance Watch: Biopharma VC Explosion Extends To Tools, Services

Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.

Topics

UsernamePublicRestriction

Register

SC143406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel